AMBFF:OTC-Ambu A/S (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 17.25

Change

-0.05 (-0.29)%

Market Cap

USD 4.15B

Volume

300.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-07 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
SEMHF Siemens Healthineers AG

-0.70 (-1.20%)

USD 65.27B
SMMNY Siemens Healthineers AG ADR

+0.08 (+0.28%)

USD 65.11B
RYLPF Koninklijke Philips N.V

N/A

USD 25.72B
SONVY Sonova Holding AG

-0.79 (-1.23%)

USD 19.36B
SONVF Sonova Holding AG

N/A

USD 19.18B
CHEOY CochLear Ltd ADR

-0.83 (-0.77%)

USD 13.96B
CHEOF Cochlear Limited

-2.54 (-1.22%)

USD 13.88B
SNNUF Smith & Nephew plc

N/A

USD 10.97B
WILYY Demant A/S ADR

N/A

USD 10.55B
WILLF Demant A/S

N/A

USD 10.50B

ETFs Containing AMBFF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.58% 74% C 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.58% 74% C 67% D+
Trailing 12 Months  
Capital Gain 20.21% 80% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.21% 79% B- 75% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 9.68% 57% F 56% F
Dividend Return 9.88% 56% F 51% F
Total Return 0.20% 36% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 61.49% 54% F 43% F
Risk Adjusted Return 16.07% 58% F 50% F
Market Capitalization 4.15B 90% A- 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.